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Available online 6 August 2016Nontransferrin-bound iron has been reported shortly
after myeloablative conditioning in patients undergoing
hematopoietic stem cell transplantation (HSCT). It is
assumed that the appearance of unbound iron in this setting
possibly reflects a major disturbance in body iron distribu-
tion, which is related mainly to its underutilization due to
erythropoiesis suppression [1,2]. Other alternative explana-
tions for the release of unbound iron in this setting include
chemotherapy-induced apoptosis of a large number of ery-
throid progenitors, and release and degradation of a large
amount of hemoglobin from them. There is a concern that
labile plasma iron (LPI), the most toxic fraction of nontrans-
ferrin-bound iron that includes the redox-active forms of
iron, may be involved in the occurrence of toxicity and
other complications commonly observed in the early post-
HSCT period [3,4].
Recently, we demonstrated that LPI levels, albeit normal
at baseline measurements, increased substantially 48 hoursafter the start of conditioning in HSCT patients, with a peak
around Day 0, and remained increased until engraftment,
when it returned to normal levels [5]. Here, we provide a
more comprehensive analysis of iron status in HSCT patients
by adding determinations of hepcidin and standard iron
parameters along with LPI levels in 25 adult patients under-
going first autologous HSCT following myeloablative condi-
tioning. This study was approved by the local Institutional
Review Board and was conducted in compliance with the
Declaration of Helsinki.
All iron parameters were determined before the start of
conditioning (baseline), on Day 0 (before stem cell infu-
sion), and on documented engraftment in 25 auto-HSCT
adult patients. Engraftment was defined as the first of 3
consecutive days with an absolute neutrophil count of at
least 0.5  109/L. LPI and standard iron parameters were
determined as previously described [5,6]. Hepcidin was
determined by the DRG Hepcidin-25 (bioactive) enzyme-
linked immunosorbent assay (DRG International, Inc., USA).
The characteristics of the study population are
summarized in Table 1. All 25 patients engrafted
(mean 12 days, range 9–16 days) and received red blood
Table 1 Patient characteristics (n = 25).
Mean age (y), range 46 (21–68)
Sex (M/F) 10/15
Underlying disease
Multiple myeloma 13
Malignant lymphoma 8
Acute leukemia 3
Seminoma 1
Disease status
Complete remission 12
Partial remission 10
Relapse, refractory 3
Previous RBC transfusions
None 12
<10 units 9
>20 units 4
Type of conditioning
Mel200 11
CVB 7
BuMel 3
Othersa 4
Note. BuMel = busulfan + melphalan; CVB = cyclophosphamide
+ BCNU + etoposide; Mel200 = melphalan 200 mg/m2; RBC = red
blood cell.
a BCNU (carmustine) + etoposide + cytarabine + melphalan
(n = 2), carmustine + etoposide + cyclophosphamide (n = 1), and
busulfan + cyclophosphamide + etoposide (n = 1).
166 F.A. Naoum et al.cell transfusion during their admission (only from Day 0 until
engraftment, mean 3 units, range 1–7 units).
The fast and substantial increase in LPI levels on Day 0
indeed reflected a disruption of iron homeostasis by condi-
tioning, which was accompanied by a response in hepcidin
and transferrin saturation (TfS) levels (Table 2). In addition,
it can be speculated that the conditioning-induced ablation
of erythropoiesis could reduce the synthesis of erythrofer-
rone, an erythroid hormone that suppresses hepcidin, favor-
ing increased hepcidin levels [7]. During the aplasia phase,
only four patients presented fever due to infectious compli-
cations, but their iron parameters were within the average
range reported in Table 2.
However, reutilization of iron by restored erythropoiesis
on engraftment leads to a substantial drop in LPI levels, but
not in hepcidin levels, possibly due to the fact that produc-
tion of hepcidin by the liver is modulated not only by iron
loading and erythropoietic activity, but also by inflamma-Table 2 Iron parameters in 25 HSCT patients.
Baseline
LPI (lM)a 0.3 ± 0.06
Hepcidin (ng/mL) 25.1 ± 3.9
Transferrin saturation (%) 40.0 ± 2.8
Ferritin (ng/mL) 733 ± 55
Note. Values represent mean ± SEM. HSCT = hematopoietic stem cell tr
mean.
a LPI levels of <0.5 lM are considered normal.
* p < .05 in relation to baseline levels.tion. Among several inflammatory stimuli reported to
induce hepcidin expression, the mechanism involving inter-
leukin-6 has been defined most clearly [8]. In fact, parallel
elevations of interleukin-6 and hepcidin levels at 1 week
after HSCT were already reported, strengthening the
hypothesized role of the inflammatory pathway, rather than
iron signals, in hepcidin synthesis until occurrence of
engraftment [9].
Baseline ferritin levels were already increased and did
not change throughout the study. This pattern was previ-
ously reported in HSCT patients, where baseline serum fer-
ritin levels were increased in a similar manner to the levels
presented in this study and also changed very little within
the first 2 weeks following HSCT [9]. The fact that many
patients underwent mobilization with chemotherapy, usu-
ally within 1 month prior to the start of conditioning, may
have contributed to increased baseline ferritin levels. As
ferritin levels take longer to return to normal compared
with hepcidin after a chemotherapy-associated inflamma-
tory episode, baseline levels could be expected to differ
between these two parameters in this study.
Considering all determinations (at baseline, on Day 0,
and on engraftment), hepcidin levels correlated positively
with ferritin (Fig. 1A) and TfS (Fig. 1B), and LPI levels corre-
lated positively with ferritin (Fig. 1C) and TfS (Fig. 1D).
Interestingly, increased LPI levels were observed with nor-
mal TfS levels in some patients. A tendency of a correlation
between hepcidin and LPI was found considering only base-
line and Day 0 levels (Fig. 1E), but was lost when engraft-
ment levels were included, possibly due to the reasons
mentioned above.
As expected, one can be concerned about the applicabil-
ity of these results to clinical practice. Previously, we
reported that baseline LPI levels could predict the occur-
rence of Grade III or IV toxicity in HSCT patients, provided
that this should be confirmed in a larger and more homoge-
neous group of patients [5]. Once the relationship between
increased LPI levels and early toxicity is confirmed,
chelation may have a role in HSCT patients. Moreover, if
chelation is to be used early in HSCT, administration of
deferasirox for 5 days, starting on the 1st day of condition-
ing, was shown to be very effective in preventing incre-
ments in LPI levels in HSCT patients [10].
Our updated results showed that cytotoxic chemother-
apy and subsequent engraftment in HSCT patients lead to
changes in all iron parameters (LPI, hepcidin, and TfS),
except for ferritin. The results indicate that, among these
iron parameters, LPI reflected better the modifications inDay 0 Engraftment
3.1 ± 0.6* 0.4 ± 0.2
40.0 ± 3.5* 39.1 ± 3.3*
70.0 ± 3.8* 47.9 ± 5.9
782 ± 47 778 ± 33
ansplantation; LPI = labile plasma iron; SEM = standard error of the
Fig. 1 Correlations between ferritin and hepcidin (A), transferrin saturation and hepcidin (B), LPI and ferritin (C), LPI and
transferrin saturation (D), and LPI and hepcidin (E) levels throughout the study. Note. LPI = labile plasma iron.
Impact of conditioning and engraftment on iron status 167iron status caused by conditioning and could serve as a tar-
get in the eventuality of chelation therapy in the early per-
iod of HSCT. The other iron parameters, including hepcidin,
were probably influenced by inflammation, even on
engraftment, and would not behave as appropriate
surrogate markers for increased LPI levels.
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